Esketamine Enhances Postoperative Sleep in Laparoscopic Surgery

Esketamine Improves Postoperative Sleep Quality

A recent randomized trial conducted at Huzhou Maternity & Child Health Care Hospital demonstrates that esketamine administration during anesthesia induction can significantly enhance early postoperative sleep quality in female patients undergoing laparoscopic surgery. The study, published in July 2026, involved 100 ASA I-II female patients aged 25-50 years, who were randomized into two groups: one receiving esketamine and the other receiving a placebo. Results showed that the esketamine group had notably better sleep quality on the first and third postoperative days, as measured by the Pittsburgh Sleep Quality Index (PSQI).

Mechanism and Context of Esketamine Use

Esketamine, a stereoisomer of ketamine, has been traditionally used for its rapid-acting antidepressant effects. In this study, esketamine was administered intravenously at a dose of 0.3 mg/kg during anesthesia induction, alongside standard anesthetics such as propofol, cisatracurium, and sufentanil. The mechanism by which esketamine improves sleep quality may be linked to its NMDA receptor antagonism, which modulates pain perception and reduces opioid requirements, thereby contributing to improved postoperative recovery.

Policy and Research Implications

The findings from this trial could have significant implications for anesthesia practices and postoperative care strategies, particularly in settings prioritizing sleep quality and opioid reduction. As healthcare systems continue to grapple with the opioid crisis, the potential of esketamine to reduce intraoperative opioid consumption and the need for postoperative rescue analgesia offers a promising avenue for reducing opioid-related risks. This study adds to the growing body of evidence supporting the broader therapeutic applications of esketamine beyond its psychiatric uses.

Risks and Unknowns

While the trial reported no significant differences in adverse event rates between the esketamine and control groups, it is crucial to consider the broader safety profile of esketamine. Long-term effects and risks associated with repeated use remain areas requiring further investigation. Additionally, the study was conducted in a single center with a specific patient demographic, which may limit the generalizability of the findings to other populations or surgical contexts.

Future Directions for Esketamine Research

Looking ahead, further research is needed to explore the applicability of esketamine in diverse surgical populations and settings. Multi-center trials with larger sample sizes could provide more robust data on its efficacy and safety. Additionally, investigating the potential benefits of esketamine in other surgical procedures or patient groups could expand its clinical utility. As the medical community continues to seek alternatives to traditional opioid analgesics, esketamine's role in enhancing postoperative recovery warrants continued exploration.